Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?
Murat AyhanŞahin LaçinDeniz Tataroğlu ÖzyükselerHeves SürmeliAkif DoğanMerve TuranHatice OdabasNedim TuranMahmut Emre YıldırımPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
COVID-19 infection is more frequent in cancer patients and tends to be more severe in metastatic cancer patients receiving anticancer treatment, and the continuation of palliative cancer treatments in these patients may cause increased cancer and infection-related morbidity and mortality.
Keyphrases
- papillary thyroid
- squamous cell
- end stage renal disease
- coronavirus disease
- small cell lung cancer
- squamous cell carcinoma
- newly diagnosed
- sars cov
- ejection fraction
- stem cells
- chronic kidney disease
- childhood cancer
- mesenchymal stem cells
- bone marrow
- peritoneal dialysis
- young adults
- combination therapy
- patient reported outcomes
- patient reported